Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
about
Antiplatelet agents for chronic kidney diseaseAntiplatelet agents for chronic kidney diseaseRisks and complications of coronary angiography: a comprehensive reviewEvaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitorsHeparin dose during percutaneous coronary intervention: how low dare we go?Noncoronary complications of coronary intervention.Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review.Rebirth of left radial artery access: could this be the 'right' radial artery?Short and long-term results after endovascular management of vascular complications during transfemoral aortic valve implantation.Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy.Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.Percutaneous coronary intervention through unintentional sheath placement in the inferior epigastric artery.Angiographic predictors of femoral access site complications: implication for planned percutaneous coronary intervention.Femoral angiogram prior to arteriotomy closure device does not reduce vascular complications in patients undergoing cardiac catheterization.Vascular access complications after cardiac catheterisation: a nurse-led quality assurance program.Technological advances in the design of catheters and devices used in renal artery interventions: impact on complications.
P2860
Q24197614-F7AFABC6-E90C-4D3A-B636-18701B3A44A2Q24200752-69CB681A-BF33-491B-B74D-E96289CBE1B0Q27025085-94C6B4E0-F628-40BE-829B-A6545A8BEE98Q28213564-DABD80F9-2BE4-4D6C-8BCC-C65058DD05BEQ34858594-9CA97957-91BB-4D26-8630-0081D5D4D8EAQ34926982-D6C7D709-31D0-4A7B-A8D1-34D7D15F0A30Q35680598-95FA5B02-C159-4319-9C24-5AD51D2B0DF7Q38497698-F99BDCB1-1FC9-4958-A2CC-2C87447B48A7Q38680555-FE9ACEB1-2A92-4AFC-8166-39F3FC86DEA4Q38971852-7A384A8E-421D-4CBD-B5A7-5A9FB639555FQ44237134-D273DACE-F251-49E1-96CB-3D6187AAC543Q46198128-67AED4DE-4958-4B5F-9228-CE3C53179AE7Q46394440-8BF414C0-A7C6-43CE-945D-1847F21A3A39Q47876669-04F229DC-A718-4083-B3A7-81C5C80F7CE6Q51414057-C74FE59C-C738-4A91-B138-F78BCA1B9A14Q51789531-F1BAF155-E3EA-4C6B-A33F-0E44EAE759AD
P2860
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@en
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@nl
type
label
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@en
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@nl
prefLabel
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@en
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@nl
P2093
P50
P1476
Modifiable risk factors for va ...... ation and Coronary Thrombosis.
@en
P2093
B H Weiner
B S George
F V Aguirre
G C Timmis
J C Blankenship
J D Talley
J E Tcheng
J S Mandak
K N Sigmon
P304
P356
10.1016/S0735-1097(98)00130-2
P407
P577
1998-06-01T00:00:00Z